BridgeBio Pharma, Inc. — Revenue by Fiscal Year
7 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/fb601193-3db4-4480-8b24-035f7324e6a4/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $502.1M | 2025-01-01 – 2025-12-31 | evidence 0001743881-26-000009 |
| FY 2024 | $221.9M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-024119 |
| FY 2023 | $9.3M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-018811 |
| FY 2022 | $77.6M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-004145 |
| FY 2021 | $69.7M | 2021-01-01 – 2021-12-31 | evidence 0000950170-22-002030 |
| FY 2020 | $8.2M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-008969 |
| FY 2019 | $40.6M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-008260 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).